Skip to main content
OpenTrials
Completed

NCT Number: NCT00671151

Effects of Low-Dose Theophylline During Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Molecular mechanisms of COPD exacerbations and the modulating effect of low dose theophylline on that inflammation are elucidated in this project. NF-kappa B-dependent pathway and acetylation status of nuclear histones are to be studied.Design: controlled, prospective and randomized study with or without theophylline, a potent HDAC activator.Objectives: 1) To determine NF-kB activation, histone deacetylase (HDAC) and histone acetyl-transferase (HAT) activity in sputum macrophages and blood monocytes during an episode of exacerbation and 3 months later, once stability is achieved. To correlate these measurements with inflammatory and oxidative stress markers and with pulmonary function and clinical variables. 2) To assess the effect of theophylline on previous molecular, functional and clinical data. Method: 25 patients with COPD will be recruited during an episode of exacerbation requiring hospitalization. NF-kB activation, HDAC and HAT activity, markers of inflammation and oxidative stress will be determined with specific assays. These determinations will be repeated once the patient is stable and compared with smokers and non smoker controls with normal lung function

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–75 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Universitario Son Dureta

Palma de Mallorca, Balearic Islands, 07014, Spain

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Severe COPD according to GOLD guidelines
  • Age between 40 and 75
  • Admission to hospital due to COPD exacerbation

Exclusion criteria

  • History of asthma
  • Pulmonary embolism
  • Pneumonia
  • Other chronic inflammatory disease
  • Patient on theophylline at the time of admission
  • Patient on oral steroids at the time of admission

Treatment and study plan

Theophylline

Drug

Theophylline 100 mg bid for 3 months

Primary outcomes

  1. HDAC activity in alveolar macrophages

    Time frame: 3 months

Secondary outcomes

  1. Lung function

    Time frame: 3 months

  2. Inflammatory cytokine release in sputum and serum

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

Hospital Universitari Son Dureta

Other

Collaborators

  • Fondo de Investigación Sanitaria (FIS)
  • Sociedad Española de Neumología y Cirugía Torácica

Registry information

Official study title

Molecular Mechanisms of COPD Exacerbations. Effect of Low-Dose Theophylline

Important dates

Study start
2005
Primary completion
2007
Study completion
2007
First posted
May 5, 2008
Registry last updated
May 5, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.